Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years.

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.